Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2021)

Design Therapeutics' Cash from Financing Activities history spans 2 years, with the latest figure at $193000.0 for Q4 2021.

  • For Q4 2021, Cash from Financing Activities rose 19200.0% year-over-year to $193000.0; the TTM value through Dec 2021 reached $379.2 million, up 751.55%, while the annual FY2025 figure was $25.7 million, 4917.15% up from the prior year.
  • Cash from Financing Activities for Q4 2021 was $193000.0 at Design Therapeutics, up from $30000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $379.0 million in Q1 2021 and bottomed at $1000.0 in Q4 2020.